Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaohan Liqi Decoction (XHLQ) is a traditional Chinese medicine (TCM) herbal formula used primarily for its anti-inflammatory effects and modulation of immune and metabolic pathways. Recent pharmacological studies have focused on its use in treating obstructive sleep apnea-hypopnea syndrome (OSAHS), where it has demonstrated efficacy in reducing airway inflammation and modulating key signaling pathways such as PI3K/Akt, HIF-1, TNF-α, and NF-κB. The decoction contains multiple active ingredients including β-sitosterol, palmitoleic acid, α-linolenic acid (ALA), kaempferol, and linoleic acid. These compounds target proteins such as ALB, IL6, CXCL8, HIF1A, IGF1, MMP9, TLR4, NOS3 and PPARG to exert their therapeutic effects. Animal studies confirm that XHLQ can decrease the expression of inflammatory cytokines like IL-6 and TNF-α while downregulating PI3K/Akt pathway activation[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiaohan Liqi Decoction.